(-0.06%) 5 063.75 points
(0.04%) 38 007 points
(-0.26%) 17 525 points
(-0.95%) $81.15
(-2.31%) $1.945
(-0.27%) $2 296.70
(0.08%) $26.68
(-0.36%) $944.80
(0.14%) $0.938
(0.26%) $11.13
(0.16%) $0.802
(0.00%) $93.45
1.60% ¥ 4 434.00
Live Chart Being Loaded With Signals
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...
Stats | |
---|---|
Dagens volum | 127 200 |
Gjennomsnittsvolum | 337 345 |
Markedsverdi | 298.64B |
EPS | ¥0 ( 2024-02-08 ) |
Neste inntjeningsdato | ( ¥39.17 ) 2024-05-09 |
Last Dividend | ¥57.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 12.37 |
ATR14 | ¥1.789 (0.04%) |
Volum Korrelasjon
Nippon Shinyaku Co., Ltd. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Nippon Shinyaku Co., Ltd. Korrelasjon - Valuta/Råvare
Nippon Shinyaku Co., Ltd. Økonomi
Annual | 2022 |
Omsetning: | ¥144.18B |
Bruttogevinst: | ¥88.20B (61.17 %) |
EPS: | ¥338.70 |
FY | 2022 |
Omsetning: | ¥144.18B |
Bruttogevinst: | ¥88.20B (61.17 %) |
EPS: | ¥338.70 |
FY | 2022 |
Omsetning: | ¥137.48B |
Bruttogevinst: | ¥87.29B (63.49 %) |
EPS: | ¥370.97 |
FY | 2021 |
Omsetning: | ¥121.89B |
Bruttogevinst: | ¥71.93B (59.02 %) |
EPS: | ¥307.37 |
Financial Reports:
No articles found.
Nippon Shinyaku Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥57.00 (N/A) |
¥0 (N/A) |
¥57.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥5.00 | 2001-03-27 |
Last Dividend | ¥57.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 45 | -- |
Total Paid Out | ¥829.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.45 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.70 | |
Div. Directional Score | 10.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9067.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7952.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7184.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6428.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5408.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4430.T | Ex Dividend Knight | 2024-05-30 | Annually | 0 | 0.00% | |
3608.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
2813.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
1433.T | Ex Dividend Junior | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
9735.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.164 | 1.500 | 6.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0974 | 1.200 | 6.75 | 8.10 | [0 - 0.3] |
returnOnEquityTTM | 0.117 | 1.500 | 9.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.331 | -1.000 | 6.69 | -6.69 | [0 - 1] |
currentRatioTTM | 5.92 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.17 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.11 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00826 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 264.20 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00953 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.646 | 1.000 | 2.57 | 2.57 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.226 | 1.000 | 7.47 | 7.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.59 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.593 | 0.800 | 9.38 | 7.50 | [0.5 - 2] |
Total Score | 13.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 12.15 | 1.000 | 8.87 | 0 | [1 - 100] |
returnOnEquityTTM | 0.117 | 2.50 | 9.88 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.85 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.331 | 1.500 | 6.69 | -6.69 | [0 - 1] |
pegRatioTTM | 0.436 | 1.500 | -0.428 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.147 | 1.000 | 8.81 | 0 | [0.1 - 0.5] |
Total Score | 6.70 |
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.